AMACR

Across TCGA pan-cancer cohorts, AMACR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMACR data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AMACR mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AMACR expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where AMACR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.888	.003	44	view →
LSCC	DFS	Tertile	II,III,IV	0.757	1.000	.007	13	view →
UCEC	DFS	Median	All	0.930	0.782	.019	4	view →
HNSC	DFS	Tertile	III,IV	0.482	0.719	.048	1	view →
GBM	OS	Median	All	0.282	0.471	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMACR–CCRCC (OS)

Open the CCRCC breakdown →